Inceptor Bio is a Morrisville, NC-based biotechnology company developing next-generation cell and gene therapy platforms, including CAR-T, CAR-M and CAR-NK. The company focuses on novel mechanisms to enhance cell performance in the tumor microenvironment and to address underserved, difficult-to-treat cancers. Core technologies cited include a co-stimulatory domain M83, the proprietary TMax manufacturing process, the K62 platform to increase macrophage phagocytosis and a differentiated iPSC technology. Inceptor partners with universities, medical centers and industry leaders to advance discovery-phase technologies into Phase I and II clinical assets. Following a $37M Series A led by Kineticos Ventures, the company plans to advance its CAR-T lead into a Phase I clinical trial and continue development of its CAR-M and CAR-NK platforms. Proceeds will also support completion of its Advanced Manufacturing Platform (AMP+), a 29,000 square foot cell and gene therapy GMP manufacturing facility in Gainesville, Florida.

Total raised

$37M

Funding rounds

1

Latest round

Series A

Latest activity

May 2022